Yahoo Finance

HMBD-002: Percheron’s immunotherapy enters Phase II planning - ICYMI

Percheron Therapeutics Ltd (ASX:PER, OTC:PERCF) last week outlined progress on its lead oncology asset HMBD-002, positioning the immunotherapy program to move into Phase II clinical testing following ...
Business Insider

Hummingbird Bioscience Announces First Patient Dosed in Phase I Clinical Trial of HMBD-501 in Advanced HER3-Expressing Solid Malignancies

HMBD-501 is a HER3-targeted ADC with a differentiated mechanism of action, engineered by Hummingbird Bioscience for optimal safety and efficacy SINGAPORE, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Hummingbird ...
WPRI 12

Hummingbird Bioscience Licenses HMBD-002, Phase II-Ready Anti-VISTA Monoclonal Antibody to Percheron Therapeutics

Percheron Therapeutics obtains exclusive worldwide rights to Hummingbird Bioscience’s anti-VISTA mAb for further clinical development Hummingbird Bioscience stands to receive up to USD 290 million in ...
Yahoo Finance

Percheron abstract accepted for AACR 2026 as HMBD-002 program heads toward Phase 2

Percheron Therapeutics Ltd (ASX:PER, OTC:PERCF) has secured acceptance of an abstract for presentation at the American Association for Cancer Research (AACR) Annual Meeting, scheduled for April 17–22, ...